Current status of immunotherapy for sarcomas. - Wikidata - awgldk - TriplyDB

Current status of immunotherapy for sarcomas.

Current status of immunotherapy for sarcomas.

http://www.wikidata.org/entity/Q49557938

about

Current status of immunotherapy for sarcomas.

http://www.wikidata.org/entity/Q49557938

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Current status of immunotherapy for sarcomas.

@en

Current status of immunotherapy for sarcomas.

@nl

type

label

Current status of immunotherapy for sarcomas.

@en

Current status of immunotherapy for sarcomas.

@nl

prefLabel

Current status of immunotherapy for sarcomas.

@en

Current status of immunotherapy for sarcomas.

@nl

P1433

Q49557938-819A3451-9928-4715-A864-B540C6856E39

P1476

Q49557938-58518E41-817E-4D02-8EAA-064575AA41FD

P2093

Q49557938-0D6516DE-47FF-46BB-8D01-F7DBF1119230

Q49557938-78A51EE6-4762-414C-AF3E-FE31DD5DB4FA

Q49557938-F6527170-8FC1-460F-A9E5-E04CF49E168D

P2860

Q49557938-05655BF4-ABE4-47A5-B704-A5AACF516B98

Q49557938-06D4B88E-BF30-4D3A-8E1C-7CA4E051333F

Q49557938-095C1708-0736-4958-977B-178DC09B2E0F

Q49557938-0CBC063E-2A95-4A03-A5C7-BC1492F0A227

Q49557938-11C60115-150A-4765-8CBD-ED6C89E7E77C

Q49557938-195C6AC2-627A-43A4-A186-725BEAF17E95

Q49557938-1BA9DFE2-5E38-4C9B-B537-B5CB3FE9B50F

Q49557938-1C0D9920-62D5-4FD2-BFF0-D1F051A7CC18

Q49557938-1E0B947A-3113-4E39-9663-274AF36889AD

Q49557938-275D87E9-6ECC-4921-97B8-A7EE47E8299B

P304

Q49557938-FED3E981-D098-4B26-A9B2-47DEC584FB3F

P31

Q49557938-E1C537A3-9CA7-49B2-8F12-98C6D5650467

P356

Q49557938-37A59975-59B3-4823-A99A-3FC37A29CC39

P433

Q49557938-7A5F047B-CDAB-4C8C-8B25-13D42442DB8E

P478

Q49557938-5DF5F969-30D4-4E45-9968-C6D9ECA6CF17

P577

Q49557938-0E50282F-D8AF-435A-88DB-5A74F0524B7F

P698

Q49557938-8BEF66FB-AD0D-4934-BEBC-69350B476C51

P921

Q49557938-89BC3EA2-08E6-448F-B6E0-CF769F9AF581

P356

P1433

P1476

Current status of immunotherapy for sarcomas.

@en

P2093

Hideji Nishida

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Tsuchiya

http://www.w3.org/2001/XMLSchema#string

Shinji Miwa

http://www.w3.org/2001/XMLSchema#string

P2860

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

Adoptive cell therapy for sarcoma

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Immunobiology of dendritic cells

Immunosuppressive strategies that are mediated by tumor cells

Phase-II trials in osteosarcoma recurrences: A systematic review of past experience.

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R

T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.

The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.

The role of CTLA-4 in the regulation of T cell immune responses.

P304

1331-1338

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT-2017-0101

http://www.w3.org/2001/XMLSchema#string

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29185391

http://www.w3.org/2001/XMLSchema#string

P921